These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 12947862)
41. Optimization of cyclosporine therapy in kidney transplantation. Remuzzi G; Perico N; Gaspari F Transplant Proc; 1998 Aug; 30(5):1673-6. PubMed ID: 9723238 [No Abstract] [Full Text] [Related]
42. The efficacy of mycophenolate mofetil treatment in the prevention of acute renal rejection is related to plasma level of mycophenolic acid. Kuriata-Kordek M; Boratyńska M; Klinger M; Woźniak M; Urbaniak J; Szyber P; Patrzalek D; Tupka D Transplant Proc; 2002 Nov; 34(7):2985-7. PubMed ID: 12431678 [No Abstract] [Full Text] [Related]
43. Comparison of trough level and C(2) cyclosporine blood concentration monitoring in outpatient kidney transplant recipients. Braun F; Armstrong VW; Lorf T; Canelo R; Arndt C; Oellerich M; Ringe B Transplant Proc; 2001; 33(7-8):3108-9. PubMed ID: 11750336 [No Abstract] [Full Text] [Related]
44. Mycophenolate sodium increases cyclosporine blood levels in renal transplant recipients. Pourfarziani V; Taheri S Saudi J Kidney Dis Transpl; 2009 Nov; 20(6):991-4. PubMed ID: 19861858 [TBL] [Abstract][Full Text] [Related]
45. Best single time points to predict the area-under-the-curve in long-term heart transplant patients taking mycophenolate mofetil in combination with cyclosporine or tacrolimus. Mardigyan V; Giannetti N; Cecere R; Besner JG; Cantarovich M J Heart Lung Transplant; 2005 Oct; 24(10):1614-8. PubMed ID: 16210138 [TBL] [Abstract][Full Text] [Related]
46. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year. Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989 [TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetics of mycophenolic acid in the early period after kidney transplantation. Wollenberg K; Krumme B; Pisarski P; Schollmeyer P; Kirste G Transplant Proc; 1998 Dec; 30(8):4090-1. PubMed ID: 9865307 [No Abstract] [Full Text] [Related]
48. Two-hour postdose concentration: a reliable marker for cyclosporine exposure in adolescents with stable renal transplants. John U; Ullrich S; Roskos M; Misselwitz J Transplant Proc; 2005 Apr; 37(3):1608-11. PubMed ID: 15866686 [TBL] [Abstract][Full Text] [Related]
49. Tacrolimus vs CyA Neoral in combination with MMF and steroids after cadaveric renal transplantation. Wang XH; Tang XD; Xu D Transplant Proc; 2000 Nov; 32(7):1702-3. PubMed ID: 11119899 [No Abstract] [Full Text] [Related]
50. Preprandial C2 monitoring of cyclosporine treatment in children with nephrotic syndrome. Fujinaga S; Kaneko K; Takada M; Ohtomo Y; Akashi S; Yamashiro Y Pediatr Nephrol; 2005 Sep; 20(9):1359-60. PubMed ID: 15918005 [No Abstract] [Full Text] [Related]
51. Clinical benefit of monitoring cyclosporine C2 and C4 in long-term liver transplant recipients. Barakat O; Peaston R; Rai R; Talbot D; Manas D Transplant Proc; 2002 Aug; 34(5):1535-7. PubMed ID: 12176472 [No Abstract] [Full Text] [Related]
52. Higher immunosuppressive efficacy of mycophenolate mofetil in combination with FK 506 than in combination with cyclosporine A. Glanemann M; Klupp J; Langrehr JM; Schröer G; Platz KP; Stange B; Settmacher U; Bechstein WO; Neuhaus P Transplant Proc; 2000 May; 32(3):522-3. PubMed ID: 10812095 [No Abstract] [Full Text] [Related]
53. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172 [TBL] [Abstract][Full Text] [Related]
54. Overestimation of mycophenolic acid by EMIT correlates with MPA metabolite. Shipkova M; Schütz E; Armstrong VW; Niedmann PD; Wieland E; Oellerich M Transplant Proc; 1999; 31(1-2):1135-7. PubMed ID: 10083508 [No Abstract] [Full Text] [Related]
55. New concepts in cyclosporine pharmacokinetic and dynamic monitoring: the impact of concomitant immunosuppression on target C2 concentrations. Brunet M; Millán O; Jiménez O; Campistol JM; Vidal E; Rojo I; Oppenheimer F; Fortuna V; Martorell J Transplant Proc; 2004 Mar; 36(2 Suppl):437S-441S. PubMed ID: 15041382 [TBL] [Abstract][Full Text] [Related]
57. Effect of diltiazem on the pharmacokinetics of microemulsion cyclosporine A in renal transplantation. Bunnag S; Vareesangthip K; Ong-ajyooth L J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S228-34. PubMed ID: 17044476 [TBL] [Abstract][Full Text] [Related]
58. Comparison of the safety and efficacy of mycophenolate mofetil, prednisolone and cyclosporine and conventional cyclosporine and prednisolone in kidney transplantation. Kim HC; Park SB; Kim HT; Cho WH; Park CH Transplant Proc; 2000 Nov; 32(7):1751-2. PubMed ID: 11119919 [No Abstract] [Full Text] [Related]
59. Conversion of C-0 to C-2 monitoring of cyclosporine in stable kidney transplant patients. Jirasiritham S; Mavichak V; Danviriyasup K; Jirasiritham S Transplant Proc; 2003 Feb; 35(1):236-7. PubMed ID: 12591379 [No Abstract] [Full Text] [Related]
60. Comparison of MPA trough levels in patients with severe diabetes mellitus and from non-diabetics after transplantation. Zanker B; Sohr B; Eder M; Frohmann E; Land W Transplant Proc; 1999; 31(1-2):1167. PubMed ID: 10083521 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]